Skip to main content

Immunicon Inks Biomarker Assay, Lab Services Deal with Merck Serono

Immunicon this week announced that it has signed a laboratory services and biomarker assay development pact with Merck Serono, the Geneva-based unit of Germany’s Merck KGaA.
 
Under the deal, Immunicon will develop specialized biomarker assays based on circulating tumor cells for an early clinical drug study. Immunicon said the new assays could potentially help doctors identify patients who have a high probability of responding to the drug being developed by Merck Serono.
 
“The ability to interrogate the extremely rare circulating cells once isolated from peripheral blood gives unprecedented opportunities to see real-time what is happening with tumor cells in patients upon exposure to investigational drugs,” Leon Terstappen, chief scientific officer of Immunicon, said in a statement.
 
Terms of the alliance were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.